Login to Your Account

Eidos armed with $27M to seek 'essence' of amyloid pathology

By Marie Powers
News Editor

Thursday, April 27, 2017

Bridgebio Pharma Inc. disclosed the second company in its growing portfolio of subsidiaries targeting genetic diseases, endowing Eidos Therapeutics with $27 million to advance its lead compound, AG-10, for the treatment of transthyretin (TTR) amyloidosis.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription